{"entity":{"id":"nct06931626","kind":"trial","name":"Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06931626 as recruiting, last updated 2026-07-24. Enrolment is 10 planned participants, an estimate. Interventions: NMS-03305293, Temozolomide. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06931626","url":"https://clinicaltrials.gov/study/NCT06931626"}],"tags":[],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["nms-03305293"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06931626","phase":"1","setting":"Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer","sponsor":"Nerviano Medical Sciences","started":"2025-08-15","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06931626/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"nms-03305293","kind":"drug","name":"NMS-03305293","route":"/drugs/nms-03305293/"}]}}